drugset / Trial / NCT00097422

OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

NCT00097422

Phase 2 Completed Optimer Pharmaceuticals LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and perform preliminary clinical evaluation in patients with mild to moderate CDAD.

Timeline

Start
2004-11-01
Primary completion
2005-04-01
Completion
2005-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fidaxomicin Other / unclassified 50 mg Oral
Subject Fidaxomicin Other / unclassified 100 mg Oral
Subject Fidaxomicin Other / unclassified 200 mg Oral

Indications